Insights into cyclosporine A-induced atherosclerotic risk in transplant recipients: Macrophage scavenger receptor regulation

Transplantation

Volumn 77, Issue 4, 2004, Pages 497-504

  Jin, Song ^a   Mathis, A Scott ^a,b   Rosenblatt, Joseph ^a   Minko, Tamara ^a   Friedman, S Gary ^c   Gioia, Kevin ^a   Serur, David S ^d   Knipp, Gregory T ^a,e  

^a RUTGERS UNIVERSITY   (United States)

^b SAINT BARNABAS MEDICAL CENTER   (United States)

^c Department of Kidney Disease ^*  (United States)

^d NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^e RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD36 ANTIGEN; CD68 ANTIGEN; CHOLESTEROL; CYCLOSPORIN A; HORMONE RECEPTOR; LECTIN; LIPID; LIVER X RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SCAVENGER RECEPTOR; SCAVENGER RECEPTOR A; SCAVENGER RECEPTOR B2; TAMM HORSFALL GLYCOPROTEIN; UNCLASSIFIED DRUG;

ARTICLE; ATHEROSCLEROSIS; BIOLOGICAL MONITORING; CELL CULTURE; CELL NUCLEUS; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DOWN REGULATION; EFFUSION; FOAM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IN VITRO STUDY; MACROPHAGE; MONOCYTE; ORGAN TRANSPLANTATION; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCREENING TEST;

ARTERIOSCLEROSIS; CELL LINE; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; GENE EXPRESSION REGULATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEINS; MACROPHAGES; MEMBRANE PROTEINS; ORGAN TRANSPLANTATION; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, IMMUNOLOGIC; RECEPTORS, LIPOPROTEIN; RISK FACTORS; RNA, MESSENGER; SCAVENGER RECEPTORS, CLASS B; SIALOGLYCOPROTEINS; TIME FACTORS; UP-REGULATION;

EID: 1442286883     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000109690.44426.20     Document Type: Article

References (30)

1. Paul LC. Chronic allograft nephropathy: an update [Review]. Kidney Int 1999; 56: 783.
2. Kasiske BL. Epidemiology of cardiovascular disease after renal transplantation. Transplantation 2001; 72(Suppl): S5.
3. Aakus S, Dahl K, Wideroe TE. Cardiovascular morbidity and risk factors in renal transplant patients. Nephrol Dial Transplant 1999; 14: 648.
4. Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000; 11: 1735.
5. Satterthwaite R, Aswad S, Sunga V, et al. Incidence of new-onset hypercholesterolemia in renal transplant patients with FK506 or cyclosporine. Transplantation 1998; 65: 446.
6. Apanay DC, Neylan JF, Ragab MS, et al. Cyclosporine increases oxidizability of low-density lipoproteins in renal transplant recipients. Transplantation 1994; 58: 663.
7. Rayyes OA, Wallmark A, Floren C-H. Additive inhibitor effect of hydrocortisone and cyclosporine on low-density lipoprotein receptor activity in cultured HepG2 cells. Hepatology 1997; 26: 967.
8. Vaziri ND, Liang K, Azad H. Effect of cyclosporine on HMG-CoA reductase, cholesterol 7α-hydroxylase, LDL receptor, HDL receptor, VLDL receptor, and lipoprotein lipase expressions. J Pharmacol Exp Ther 2000; 294: 778.
9. Nakata A, Nakagawa Y, Nishida M, et al. CD36, a novel receptor for oxidized low-density lipoproteins, is highly expressed on lipid-laden macrophages in human atherosclerotic aorta. Arterioscler Thromb Vasc Biol 1999; 19: 1333.
10. Ramprasad MP, Terpstra V, Kondratenko N, et al. Cell surface expression of mouse macrosialin and human CD68 and their role as macrophage receptors for oxidized low density lipoprotein. Proc Natl Acad Sci U S A 1996; 93: 14833.
11. Horvai A, Palinski W, Wu H, et al. Scavenger receptor A gene regulatory elements target gene expression to macrophages and to foam cells of atherosclerotic lesions. Proc Natl Acad Sci U S A 1995; 92: 5391.
12. Webb NR, Connell PM, Graf GA, et al. SR-BII, an isoform of the scavenger receptor BI containing an alternate cytoplasmic tail, mediates lipid transfer between high density lipoprotein and cells. J Biol Chem 1998; 273: 15241.
13. Li D, Mehta JL. Antisense to LOX-1 inhibits oxidized LDL-mediated upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells. Circulation 2000; 101: 2889.
14. Moore KJ, Rosen ED, Fitzgerald ML, et al. The role of PPAR-γ in macrophage differentiation and cholesterol uptake. Nat Med 2001; 7: 41.
15. Venkateswaran A, Laffitte BA, Joseph SB, et al. Control of cellular cholesterol efflux by nuclear oxysterol receptor LXRα. Pro Natl Acad Sci U S A 2000; 97: 12097.
16. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156.
17. de Vries HE, Buchner B, van Berkel TJ, et al. Specific interaction of oxidized low-density lipoprotein with macrophage-derived foam cells isolated from rabbit atherosclerotic lesions. Arterioscler Throm Vasc Biol 1999; 19: 638.
18. Terpstra V, Kondratenko N, Steinberg D. Macrophages lacking scavenger receptor A show a decrease in binding and uptake of acetylated low-density lipoprotein and of apoptotic thymocytes, but not of oxidatively damaged red blood cells. Proc Natl Acad Sci U S A 1997; 94: 8127.
19. Sugano R, Yamamura T, Harada-Shiba M, et al. Uptake of oxidized low-density lipoprotein in a THP-1 cell line lacking scavenger receptor A. Atherosclerosis 2001; 158: 351.
20. Febbraio M, Podrez EA, Smith JA, et al. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest 2000; 105: 1049.
21. Sparrow CP, Baffic J, Lam MH, et al. A potent synthetic LXR agonist is more effective than cholesterol-loading at inducing ABCA1 mRNA and stimulating cholesterol efflux. J Biol Chem 2002; 277: 10021.
22. Chawla A, Boisvert WA, Lee CH, et al. A PPAR-gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Moll Cell 2001; 7: 161.
23. Febbraio M, Hajjar DP, Silverstein RL. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest 2001; 108: 785.
24. van Dam MJ, de Groot E, Clee SM, et al. Association between increased arterial-wall thickness and impairment of ABCA1-driven cholesterol efflux: an observational study. Lancet 2002; 359: 37.
25. Anderson HO, Qvortrup K, Rostgaard J, et al. Effect of cyclosporine during initiation of transplant arteriosclerosis. An ultrasound study in the aorta-transplanted rabbit. Atherosclerosis 1997; 133: 171.
26. Roselaar SE, Schonfeld G, Daugherty A. Enhanced development of atherosclerosis in cholesterol-fed rabbits by suppression of cell-mediated immunity. J Clin Invest 1995; 96: 1389.
27. van Joost T, Kozel MM, Tank B, et al. Cyclosporine in atopic dermatitis. Modulation in the expression of immunologic markers in lesional skin. J Am Acad Dermatol 1992; 27: 922.
28. Prens EP, van Joost T, Hegmans JP, et al. Effects of cyclosporine on cytokines and cytokine receptors in psoriasis. J Am Acad Dermatol 1995; 33: 947.
29. Varghese Z, Fernando RL, Turakhia G, et al. Oxidizability of low-density lipoproteins from Neoral and tacrolimus treated renal transplant patients. Transplant Proc 1998; 30: 2043.
30. Ricciarelli R, Zingg J-M, Azzi A. Vitamin E reduces the uptake of oxidized LDL by inhibiting CD36 scavenger receptor expression in cultured aortic smooth muscle cells. Circulation 2000; 102: 82.